Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04365764

Enrollment

400

Registered

2020-04-28

Start date

2020-03-14

Completion date

2022-12-31

Last updated

2023-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ARDS, Covid-19, Pneumonia

Brief summary

Several treatments have been used in during the Covid-19 pandemic of 2020. Using patients' registries from several hospitals in Paris, the investigators retrospectively analyzed associations between specific treatments, including but not limited to vaccines targeted against SARS-CoV-2, hydroxychloroquine, azithromycin, remdesivir, baricitinib, tocilizumab, sarilumab, lopinavir/ritonavir and oseltamivir; and clinical outcomes including, death and mechanical ventilation.

Detailed description

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* admitted for severe Covid-19 pneumonia (i.e. requiring O2-support more than 6L/min with SpO2\<96%)

Exclusion criteria

* patients who were previously in ICU * patients already hospitalized prior to study start date * patients in palliative care * lack of consent

Design outcomes

Primary

Measure	Time frame	Description
Composite of death and mechanical ventilation	14-days follow-up	Composite of death and mechanical ventilation (i.e. intubation)

Secondary

Measure	Time frame	Description
Death	14-days follow-up	Death
Mechanical ventilation	14-days follow-up	Enabled by intubation
Composite of death and mechanical ventilation	28-days follow-up	Composite of death and mechanical ventilation
World Health Organization score	14-days follow-up	World Health Organization score

Countries

France

Outcome results